European Journal of Cardiovascular Medicine

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, and elevated low-density lipoprotein cholesterol (LDL-C) is a well-established causal determinant of atherosclerotic events. Large randomized trials and meta-analyses have demonstrated that lowering LDL-C with statins reduces major vascular events in a broadly proportional manner to the absolute reduction achieved.¹ Consequently, statins remain the foundation of lipid-lowering treatment for both primary and secondary cardiovascular prevention.

The clinical effectiveness of statin therapy, however, depends on long-term adherence and persistence. Adverse symptoms attributed to statins, particularly muscle-related complaints, represent an important reason for dose reduction, discontinuation, and failure to achieve recommended LDL-C targets. The term “statin intolerance” is challenging because it has historically been applied to several different phenomena, ranging from any symptom temporally associated with statin exposure to reproducible intolerance verified by withdrawal and rechallenge.²

The National Lipid Association defines statin intolerance as one or more adverse effects associated with statin therapy that improve with dose reduction or discontinuation and distinguishes complete intolerance from partial intolerance. Importantly, at least two statins should generally be attempted, including one at the lowest approved dosage, before a patient is classified as statin-intolerant.² The International Lipid Expert Panel similarly emphasizes clinical verification and exclusion of potentially reversible contributors.³

The magnitude of the problem depends substantially on the method used to identify it. In a meta-analysis encompassing more than four million patients, Bytyçi et al. reported an overall prevalence of statin intolerance of approximately 9%, with substantially lower estimates in randomized controlled trials than in observational studies.⁴ Randomized N-of-1 investigations have further demonstrated that a considerable proportion of symptoms experienced during statin therapy also occur during placebo treatment. The SAMSON trial demonstrated substantial symptom burden during placebo periods, while the StatinWISE series similarly found little overall difference in muscle symptoms between statin and placebo periods.⁵,⁶ These observations support an important contribution from expectation-related nocebo or drucebo effects.³

Nevertheless, genuine pharmacological toxicity exists. High statin doses, drug interactions, advanced age, comorbidities, and genetic variation can increase systemic statin exposure and myotoxic risk. The SEARCH genome-wide association study identified a strong association between the SLCO1B1 c.521T>C variant and simvastatin-induced myopathy.⁷ Observational studies such as PRIMO have also demonstrated clinically relevant muscle symptoms in patients receiving high-dose statin therapy.⁸

There remains relatively limited prospective evidence applying multiple formal definitions simultaneously to the same Indian cohort. Differences in background dyslipidaemia, vitamin D status, polypharmacy, pharmacokinetics, and access to care further justify population-specific evaluation. Therefore, this study prospectively determined the incidence of statin intolerance in statin-naïve patients, compared four operational definitions, examined the relationship with statin type and intensity, and identified demographic, biochemical, and pharmacological predictors.

Study Design and Participants

A prospective observational longitudinal cohort study was conducted at a tertiary care teaching centre. The incidence cohort consisted of consecutive adults aged ≥18 years who were statin-naïve and had a documented clinical indication for statin treatment. Statin-naïve status was defined as no exposure during the preceding 12 months and no lifetime cumulative exposure exceeding 30 days.

Patients were excluded if they were pregnant or lactating, had baseline creatine kinase (CK) >5 times the upper limit of normal, active liver disease or transaminase elevation >3 times the upper limit of normal, primary inflammatory or hereditary muscle disease, severe renal dysfunction with estimated glomerular filtration rate <30 mL/min/1.73 m², dialysis dependence, active malignancy with limited life expectancy, or inability to provide reliable informed consent.

Five hundred patients were enrolled and followed prospectively. A minimum 12-month follow-up was planned for each participant.

Baseline Assessment

Demographic, anthropometric, clinical and medication data were recorded using a structured case record form. Information included age, sex, body mass index, cardiovascular prevention category, diabetes, hypertension, chronic kidney disease, thyroid disease, tobacco exposure, polypharmacy, and concomitant medications capable of interacting with statins.

Laboratory assessment included fasting lipid profile, CK, alanine aminotransferase, renal function, glucose/HbA1c, thyroid-stimulating hormone, and 25-hydroxyvitamin D. LDL-C was primarily estimated using the Martin-Hopkins approach, with direct measurement where required.

Follow-up and Ascertainment of Intolerance

Participants underwent scheduled evaluation at baseline, 2 weeks by telephone, 6 weeks, and 3, 6, 9 and 12 months. Unscheduled evaluation was permitted whenever symptoms developed.

Suspected statin-associated symptoms were systematically characterized with regard to onset, anatomical distribution, severity, relationship to statin initiation or dose escalation, and functional effects. Muscle symptoms were assessed using the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI), which categorized causality as unlikely, possible or probable.²

Potential secondary causes including hypothyroidism, vitamin D deficiency, interacting medication, strenuous exercise, uncontrolled metabolic disease and alternative musculoskeletal diagnoses were evaluated. Where clinically appropriate, supervised statin dechallenge for at least four weeks was followed by rechallenge using a modified dose, alternative statin or intermittent regimen.

Statin intolerance was classified separately according to NLA, ILEP, EAS and LLAC/CCWG criteria.²,³

Statistical Analysis

Continuous variables were summarized as mean±SD or median with interquartile range according to distribution; categorical variables were reported as number and percentage. Between-group comparisons used appropriate parametric or non-parametric tests and chi-square/Fisher exact tests for categorical variables.

Cumulative incidence was calculated among participants completing follow-up. Agreement between definitions was assessed using Cohen's kappa. Logistic regression was performed to identify independent predictors of confirmed statin intolerance. Adjusted odds ratios (aOR) with 95% confidence intervals were reported. A two-sided p value <0.05 was considered statistically significant.

Of 500 statin-naïve patients enrolled, 462 completed follow-up. Ninety-seven participants (21.0%) reported at least one suspected adverse effect, 61 (13.2%) discontinued or reduced treatment without medical advice, and 48 (10.4%) ultimately satisfied NLA criteria for statin intolerance.

Table 1. Selected baseline characteristics of the incidence cohort

The population therefore contained substantial cardiovascular comorbidity and exposure to recognized contributors to statin-related symptoms, particularly polypharmacy and vitamin D deficiency.

Table 2. Incidence according to different definitions

The estimate therefore varied by approximately 40% depending solely on the operational definition applied to the same cohort. Agreement with the NLA definition was highest for ILEP criteria.

Table 3. Self-reported and confirmed intolerance

Thus, fewer than half of those reporting suspected adverse effects ultimately had confirmed intolerance, and partial intolerance was more frequent than complete intolerance.

Table 4. Statin intensity and interacting medication

There was a significant trend across statin intensity categories (p=0.002). The association with concomitant CYP3A4-interacting medication was also significant (p=0.003).

Table 5. Independent predictors of confirmed statin intolerance

The model showed fair discrimination with an area under the ROC curve of 0.72.

The present prospective study found a 12-month incidence of confirmed statin intolerance of 10.4% according to NLA criteria. This finding is closely aligned with the overall estimate reported by Bytyçi et al., whose meta-analysis of 176 studies and more than four million patients estimated statin intolerance at approximately 9%.⁴ Importantly, that analysis demonstrated a major difference between randomized trials and observational studies, with substantially lower prevalence in blinded randomized populations. Our estimate lies between these settings, which is biologically and methodologically plausible for a prospective but unblinded real-world cohort applying formal diagnostic criteria.

A central finding was the substantial discrepancy between symptoms and confirmed intolerance. While 21.0% reported at least one suspected adverse effect, only 10.4% fulfilled NLA criteria. This distinction is consistent with experimental evidence from SAMSON and StatinWISE. Wood et al. demonstrated that most symptom burden reported during statin treatment could also be reproduced during placebo exposure, while StatinWISE likewise found no substantial overall difference in muscle symptom scores between statin and placebo periods.⁵,⁶ The present finding that prior negative statin information was the strongest independent predictor (aOR 3.04) further supports an important expectation-related component. Penson et al. have described this as a nocebo/drucebo phenomenon that should be explicitly addressed rather than interpreted as evidence that symptoms are fabricated.³

A second important finding was variation according to diagnostic definition. The incidence ranged from 8.0% to 11.3% when four recognized criteria were applied to the same individuals. The NLA definition captures a broader spectrum of adverse effects while requiring adequate attempts with alternative statins, whereas the EAS framework primarily emphasizes muscle symptoms and temporal relationships.² Such definitional heterogeneity helps explain why reported frequencies across studies differ markedly.

A dose-related signal was also observed. High-intensity statin treatment was associated with a 14.8% intolerance rate compared with 7.9% with moderate-intensity treatment and remained independently associated after adjustment. This supports a genuine pharmacological component in a subset of patients. PRIMO similarly documented muscle symptoms in patients receiving high-dose statin therapy in routine practice.⁸

Drug interactions were among the strongest modifiable predictors. Patients receiving CYP3A4-interacting drugs had more than twice the rate of intolerance. Medication review should therefore be a routine part of intolerance assessment. Vitamin D deficiency was also independently associated with intolerance. Although the causal benefit of supplementation for SAMS remains uncertain, identifying and correcting deficiency remains reasonable because deficiency itself may produce musculoskeletal symptoms.

Older age and female sex were modest independent predictors, broadly consistent with previously reported risk profiles.⁴ In contrast, no single baseline characteristic provided sufficiently strong discrimination to justify withholding treatment. Statin therapy should therefore not be avoided on the basis of risk factors alone; instead, such factors should trigger counselling, review of interacting drugs, and closer monitoring.

The major strengths were prospective ascertainment, parallel application of multiple definitions, longitudinal follow-up, and formal assessment of suspected adverse effects. Limitations include the single-centre design, open-label symptom ascertainment and rechallenge, and a limited number of confirmed events for multivariable modelling.

Confirmed statin intolerance developed in approximately one in ten statin-naïve patients during 12 months of follow-up, whereas suspected adverse effects were reported by approximately one in five. The estimated frequency varied substantially according to the diagnostic definition used. High-intensity therapy, CYP3A4 drug interactions, vitamin D deficiency, older age, female sex, and prior exposure to negative information about statins were independently associated with intolerance. These results support rigorous assessment and correction of modifiable contributors before a patient is permanently labelled statin-intolerant.

1.      Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.

2.      Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin-intolerant patient. J Clin Lipidol. 2022;16(4):361-375.

3.      Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel. J Cachexia Sarcopenia Muscle. 2022;13(3):1596-1622.

4.      Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213-3223.

5.      Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182-2184.

6.      Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135.

7.      SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789-799.

8.      Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-414.

9.      Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in ASCOT-LLA. Lancet. 2017;389(10088):2473-2481.

10.   Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.

11.   Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167(4):221-227.

12.   Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014;9(5):e96808.